FdaApplication
BLA 125603
Identifiers
- fda_app_no: BLA125603
Properties
| Property | Value |
|---|---|
| applicant_name | Vericel Corporation |
| application_type | BLA |
| approval_date | 2016-12-13 |
Revenue by product
MACI
| Period | Revenue |
|---|---|
| Q2 2026 | $65.5M |
| Q1 2026 | $56.4M |
| Q4 2025 | $84.1M |
| Q3 2025 | $55.7M |
| Q2 2025 | $53.5M |
| Q1 2025 | $46.3M |
| Q4 2024 | $68.3M |
| Q3 2024 | $44.7M |
| Q2 2024 | $44.1M |
| Q1 2024 | $40.2M |
| Q4 2023 | $56.7M |
| Q3 2023 | $37.6M |
| Q2 2023 | $36.3M |
| Q1 2023 | $34.2M |
| Q4 2022 | $46.4M |
| Q3 2022 | $31.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| MACI | — | 500,000 CM2 CM2 | Cell Sheets |
1 product